Tessera Therapeutics
Bill joined Tessera in April of 2021 as Senior Vice President of Therapeutic Discovery and Translational Sciences. He brings a strong background in genetic medicines and a passion for rare disease drug development with over 15 years of experience leading cross-functional teams from early discovery through clinical trials.
Before joining Tessera, Bill held the position of Vice President and Fabry Program Lead at AVROBIO. Prior to that, as Senior Director at Synlogic, he led clinical program teams in PKU and urea cycle disorders. Earlier in his career, he spent 12 years at Alnylam Pharmaceuticals where he made important contributions to the maturation of both the siRNA delivery platforms and therapeutic pipeline. Bill led the discovery and early clinical development of GIVLAARI® (givosiran) for the treatment of acute hepatic porphyria, which was the first FDA-approved RNAi therapeutic utilizing GalNAc conjugate technology.
He holds a B.S. in Biology from SUNY Geneseo and a Ph.D. from Brown University.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.